Matches in SemOpenAlex for { <https://semopenalex.org/work/W4291172221> ?p ?o ?g. }
- W4291172221 endingPage "100620" @default.
- W4291172221 startingPage "100620" @default.
- W4291172221 abstract "Vascularization is fundamental to the growth and spread of tumor cells to distant sites. As a consequence, angiogenesis, the sprouting of new blood vessels from existing ones, is a characteristic trait of cancer. In 1971, Judah Folkman postulated that tumour growth is angiogenesis dependent and that by cutting off blood supply, a neoplastic lesion could be potentially starved into remission. Decades of research have been devoted to understanding the role that vascular endothelial growth factor (VEGF) plays in tumor angiogenesis, and it has been identified as a significant pro-angiogenic factor that is frequently overexpressed within a tumor mass. Today, anti-VEGF drugs such as Sunitinib, Sorafenib, Axitinib, Tanibirumab, and Ramucirumab have been approved for the treatment of advanced and metastatic cancers. However, anti-angiogenic therapy has turned out to be more complex than originally thought. The failure of this therapeutic option calls for a reevaluation of VEGF as the major target in anti-angiogenic cancer therapy. The call for reassessment is based on two rationales: first, tumour blood vessels are abnormal, disorganized, and leaky; this not only prevents optimal drug delivery but it also promotes hypoxia and metastasis; secondly, tumour growth or regrowth might be blood vessel dependent and not angiogenesis dependent as tumour cells can acquire blood vessels via non-angiogenic mechanisms. Therefore, a critical assessment of VEGF, VEGFRs, and their inhibitors could glean newer options such as repurposing anti-VEGF drugs as vascular normalizing agents to enhance drug delivery of immune checkpoint inhibitors." @default.
- W4291172221 created "2022-08-13" @default.
- W4291172221 creator A5006968966 @default.
- W4291172221 creator A5043321294 @default.
- W4291172221 creator A5048634945 @default.
- W4291172221 creator A5059314404 @default.
- W4291172221 creator A5067135972 @default.
- W4291172221 creator A5083211956 @default.
- W4291172221 creator A5084240589 @default.
- W4291172221 creator A5090065291 @default.
- W4291172221 date "2022-01-01" @default.
- W4291172221 modified "2023-10-16" @default.
- W4291172221 title "Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy" @default.
- W4291172221 cites W1477040914 @default.
- W4291172221 cites W1589323083 @default.
- W4291172221 cites W1597158509 @default.
- W4291172221 cites W1612634664 @default.
- W4291172221 cites W1842084427 @default.
- W4291172221 cites W1875150791 @default.
- W4291172221 cites W1889335134 @default.
- W4291172221 cites W1907991309 @default.
- W4291172221 cites W1921704765 @default.
- W4291172221 cites W1963681473 @default.
- W4291172221 cites W1969328947 @default.
- W4291172221 cites W1971993769 @default.
- W4291172221 cites W1979598304 @default.
- W4291172221 cites W1985043086 @default.
- W4291172221 cites W1992112921 @default.
- W4291172221 cites W1993880149 @default.
- W4291172221 cites W1998400323 @default.
- W4291172221 cites W2000000541 @default.
- W4291172221 cites W2013818100 @default.
- W4291172221 cites W2013863072 @default.
- W4291172221 cites W2017322644 @default.
- W4291172221 cites W2026996188 @default.
- W4291172221 cites W2029470215 @default.
- W4291172221 cites W2032347891 @default.
- W4291172221 cites W2032716364 @default.
- W4291172221 cites W2035183057 @default.
- W4291172221 cites W2050499474 @default.
- W4291172221 cites W2053221827 @default.
- W4291172221 cites W2054034979 @default.
- W4291172221 cites W2056837993 @default.
- W4291172221 cites W2063027760 @default.
- W4291172221 cites W2063620817 @default.
- W4291172221 cites W2075873658 @default.
- W4291172221 cites W2077129920 @default.
- W4291172221 cites W2080202443 @default.
- W4291172221 cites W2081633887 @default.
- W4291172221 cites W2088781488 @default.
- W4291172221 cites W2089078929 @default.
- W4291172221 cites W2097089862 @default.
- W4291172221 cites W2099087398 @default.
- W4291172221 cites W2102140960 @default.
- W4291172221 cites W2104759721 @default.
- W4291172221 cites W2111237964 @default.
- W4291172221 cites W2111792559 @default.
- W4291172221 cites W2117282734 @default.
- W4291172221 cites W2117692326 @default.
- W4291172221 cites W2121243662 @default.
- W4291172221 cites W2123060447 @default.
- W4291172221 cites W2130522035 @default.
- W4291172221 cites W2131515450 @default.
- W4291172221 cites W2135808678 @default.
- W4291172221 cites W2136601558 @default.
- W4291172221 cites W2137297789 @default.
- W4291172221 cites W2138787512 @default.
- W4291172221 cites W2143816609 @default.
- W4291172221 cites W2149158668 @default.
- W4291172221 cites W2151637779 @default.
- W4291172221 cites W2152529303 @default.
- W4291172221 cites W2156453405 @default.
- W4291172221 cites W2156902079 @default.
- W4291172221 cites W2157687487 @default.
- W4291172221 cites W2157769714 @default.
- W4291172221 cites W2158303916 @default.
- W4291172221 cites W2167351436 @default.
- W4291172221 cites W2168427108 @default.
- W4291172221 cites W2172778470 @default.
- W4291172221 cites W2204695292 @default.
- W4291172221 cites W2277879584 @default.
- W4291172221 cites W2288373908 @default.
- W4291172221 cites W2293809486 @default.
- W4291172221 cites W2295851099 @default.
- W4291172221 cites W2347033746 @default.
- W4291172221 cites W2398876361 @default.
- W4291172221 cites W2413772354 @default.
- W4291172221 cites W2425731878 @default.
- W4291172221 cites W2550507133 @default.
- W4291172221 cites W2551234403 @default.
- W4291172221 cites W2586781596 @default.
- W4291172221 cites W2597795073 @default.
- W4291172221 cites W2600452401 @default.
- W4291172221 cites W2606131767 @default.
- W4291172221 cites W2624827575 @default.
- W4291172221 cites W2626381435 @default.
- W4291172221 cites W2724312948 @default.
- W4291172221 cites W2729588720 @default.